Animal trial backs use of RTI's BioCleanse process
This article was originally published in Clinica
Executive Summary
The BioCleanse tissue sterilisation process, developed by RTI Biologics, allows meniscal allografts to perform to the same standard as those that underwent standard aseptic processing, a trial has shown.
You may also be interested in...
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.